Phase II Study of Adaptive Switching of FOLFIRINOX or Gemcitabine/Nab-Paclitaxel as a Neoadjuvant Strategy for Patients with Resectable and Borderline Resectable/Locally Advanced Unresectable Pancreatic Cancer (NeoOPTIMIZE)
The purpose of this phase II trial is to evaluate the safety and efficacy of the early switching from FOLFIRINOX regimen to a combination of gemcitabine and nab-paclitaxel before surgery in patients with resectable, borderline resectable, or locally advanced pancreatic cancer.
Study ID: STUDY00021614
Trial Phase: Phase II
Trial Sponsor: OHSU Knight Cancer Institute
Therapies Used in This Trial: Nab-paclitaxel, FOLFIRINOX